Form 4: Catalyst Pharmaceuticals Director Denkhaus Exercises Stock Options

Director Donald A. Denkhaus of Catalyst Pharmaceuticals exercised stock options, acquiring 4,000 shares of common stock on February 14, 2025.

Summary

• On February 14, 2025, Donald A. Denkhaus, a director of Catalyst Pharmaceuticals, exercised restricted stock units.
• This transaction resulted in the acquisition of 4,000 shares of common stock.
• Following the transaction, Denkhaus directly owns 495,079 shares of Catalyst Pharmaceuticals.
• The restricted stock units vested in three equal tranches on February 14, 2023, February 14, 2024, and February 14, 2025.
• The final tranche of shares was delivered on February 14, 2025.

Sentiment

Score: 5

Explanation: This is a neutral event, simply reflecting the standard vesting and exercise of stock options by a company director. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is a routine insider transaction.

Key Dates